Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial


Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as maintenance therapy after first-line chemotherapy have improved progression-free survival in women with advanced ovarian cancer; however, not all PARP inhibitors can provide benefit for a biomarker-unselected population. Senaparib is a PARP inhibitor that demonstrated antitumor activity in patients with solid tumors, including ovarian cancer, in phase 1 studies. The multicenter, double-blind, phase 3 trial FLAMES randomized (2:1) 404 females with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III–IV) and response to first-line platinum-based chemotherapy to senaparib 100 mg (n = 271) or placebo (n = 133) orally once daily for up to 2 years. The primary endpoint was progression-free survival assessed by blinded independent central review. At the prespecified interim analysis, the median progression-free survival was not reached with senaparib and was 13.6 months with placebo (hazard ratio 0.43, 95% confidence interval 0.32–0.58; P < 0.0001). The benefit with senaparib over placebo was consistent in the subgroups defined by BRCA1 and BRCA2 mutation or homologous recombination status. Grade ≥3 treatment-emergent adverse events occurred in 179 (66%) and 27 (20%) patients, respectively. Senaparib significantly improved progression-free survival versus placebo in patients with advanced ovarian cancer after response to first-line platinum-based chemotherapy, irrespective of BRCA1 and BRCA2 mutation status and with consistent benefits observed between homologous recombination subgroups, and was well tolerated. These results support senaparib as a maintenance treatment for patients with advanced ovarian cancer after a response to first-line chemotherapy. identifier: NCT04169997.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Trial profile.
Fig. 2: Progression-free survival by BICR in the ITT population.
Fig. 3: Progression-free survival in the subgroups of patients with and without BRCA1 and BRCA2 mutations.
Fig. 4: Progression-free survival by investigator review in the ITT population.

Similar content being viewed by others

Data availability

The study protocol is published with this manuscript as Supplementary Information. All extracted data, including deidentified individual information, trial-level data (analysis datasets) and other information (for example, clinical study reports and informed consent form) are available from the corresponding author upon request, provided the FLAMES trial is not part of an ongoing or planned regulatory submission. The corresponding author will also accept requests for clinical trial data for unlicensed products and indications.


  1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

    Article  PubMed  Google Scholar 

  2. National Cancer Institute. Cancer stat facts: ovarian cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program 2013–2019 (2019).

  3. National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 2.2023. NCCN (2022).

  4. Berek, J. S., Renz, M., Kehoe, S., Kumar, L. & Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int. J. Gynaecol. Obstet. 155, 61–85 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  5. González-Martín, A. et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 833–848 (2023).

    Article  PubMed  Google Scholar 

  6. DiSilvestro, P. & Alvarez Secord, A. Maintenance treatment of recurrent ovarian cancer: is it ready for prime time? Cancer Treat. Rev. 69, 53–65 (2018).

    Article  CAS  PubMed  Google Scholar 

  7. O’Malley, D. M., Krivak, T. C., Kabil, N., Munley, J. & Moore, K. N. PARP inhibitors in ovarian cancer: a review. Target. Oncol. 18, 471–503 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Huang, X.-Z. et al. Efficacy and prognostic factors for PARP inhibitors in patients with ovarian cancer. Front. Oncol. 10, 958 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).

    Article  CAS  PubMed  Google Scholar 

  10. Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).

    Article  CAS  PubMed  Google Scholar 

  11. González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).

    Article  PubMed  Google Scholar 

  12. Monk, B. J. et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). J. Clin. Oncol. 40, 3952–3964 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. ZEJULA (niraparib) prescribing information. GlaxoSmithKline (2022).

  14. RUBRACA (rucaparib) prescribing information. Pharma and Schweiz GmbH (2023).

  15. Coleman, R. L. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 381, 2403–2415 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

    Article  CAS  Google Scholar 

  17. Cai, S. X. et al. Abstract 1399: discovery and development of PARP inhibitor senaparib. Cancer Res. 82, 1399 (2022).

    Article  Google Scholar 

  18. Cao, J. et al. Safety, tolerability, and pharmacokinetics of senaparib, a novel PARP1/2 inhibitor, in Chinese patients with advanced solid tumors: a phase I trial. Oncologist 28, e1259–e1267 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Gao, B. et al. A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer 129, 1041–1050 (2023).

    Article  CAS  PubMed  Google Scholar 

  20. Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721–1731 (2021).

    Article  CAS  PubMed  Google Scholar 

  21. Li, N. et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1230–1237 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  22. de Souza, P. et al. 574P updated results of phase I study of senaparib (IMP4297) in Australian patients with advanced solid tumours. Ann. Oncol. 31, S490 (2020).

    Article  Google Scholar 

  23. Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer. AstraZeneca (2022).

  24. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute (2017).

Download references


This study was funded by IMPACT Therapeutics (Shanghai) Inc. The sponsor had a role in the study design, data collection, data analysis, data interpretation and writing and approval of this manuscript for publication. The authors wish to acknowledge and thank the study patients and their families, the investigators and the study teams at each of the participating centers, as well as S.X. Cai, Y. Tian, H. Xia, B. Li and Y. Zhang of IMPACT Therapeutics (Shanghai) Inc. and the entire research team of the FLAMES trial. Writing and editorial assistance was provided by J. Kolston and M. Yu at Parexel and was funded by IMPACT Therapeutics (Shanghai) Inc.

Author information

Authors and Affiliations




X.Wu and J.L. were the cochief investigators for this trial and are co-first authors of the manuscript. X.Wu, J.L., J.W., L.W. and Z.Lin contributed to the trial design and were involved in project administration and supervision. All authors contributed to patient accrual, trial conduct, treatment, safety assessments and data acquisition. All authors had full access to and verified the data in this study. All authors interpreted the data, reviewed the draft and final versions of the manuscript and provided final approval to submit this article for publication.

Corresponding author

Correspondence to Xiaohua Wu.

Ethics declarations

Competing interests

C.X. and C.-Y.H. are employees of IMPACT Therapeutics (Shanghai) Inc., Shanghai, China. The other authors declare no competing interests.

Peer review

Peer review information

Nature Medicine thanks Michael Friedlander and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ulrike Harjes, in collaboration with the Nature Medicine team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1

Structures of senaparib, olaparib, niraparib, and rucaparib.

Extended Data Fig. 2 Chemotherapy-free interval, time to first subsequent therapy or death, and time to treatment discontinuation or death.

Kaplan–Meier estimates of chemotherapy-free interval (a), time to first subsequent therapy or death (b), and time to treatment discontinuation or death (c) in the ITT population. CFI, chemotherapy-free interval; CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; n/N, number with disease progression or death/total number evaluable; NR, not reached; TDT, time to treatment discontinuation or death; TFST, time to first subsequent therapy or death.

Extended Data Table 1 Baseline characteristics in patients who had evaluable data for homologous-recombination status
Extended Data Table 2 Exploratory subgroup analysis of progression-free survival according to homologous-recombination status
Extended Data Table 3 Summary of adverse events in the safety analysis set
Extended Data Table 4 Serious treatment-emergent adverse events occurring in at least 1% of patients in either treatment arm
Extended Data Table 5 Sequencing of dose amendments to manage toxicity
Extended Data Table 6 Management of nonhematological and hematological toxicities
Extended Data Table 7 Study endpoints

Supplementary information

Supplementary Information

Supplementary Methods and Study Protocol.

Reporting Summary

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, X., Liu, J., Wang, J. et al. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Nat Med 30, 1612–1621 (2024).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing